Physician profile
Antiem Bui
NPI 1336569300
$3,901.49
in general payments reported to CMS, 2019-2025
16 companies · $723 in 2025
The $723 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $125 · 2021: $636 · 2022: $384 · 2023: $691 · 2024: $944 · 2025: $723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,336 · Education: $22.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,335.52 |
| Education | $22.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $962.34 | 2021-2025 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $791.59 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $502.07 | 2021-2025 | |
| Glaxosmithkline, LLC. | $273.38 | 2021-2023 | Benlysta |
| Ardelyx, INC. | $240.33 | 2024 | Xphozah 30 Mg |
| Alexion Pharmaceuticals, INC. | $219.76 | 2019-2022 | |
| Shockwave Medical, INC | $164.71 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novartis Pharmaceuticals Corporation | $164.03 | 2024-2025 | |
| Vifor Pharma, INC. | $128.13 | 2021-2024 | |
| Calliditas Therapeutics US INC. | $125.00 | 2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $119.92 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.35 | 2024 | Jardiance |
| Fresenius USA Marketing, INC. | $55.80 | 2019 | |
| Opko Pharmaceuticals, LLC | $25.38 | 2024 | Rayaldee |
| Amgen INC. | $22.35 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $22.35 | 2023-2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antiem Bui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.